Live Breaking News & Updates on Abbvie immunogen

Stay informed with the latest breaking news from Abbvie immunogen on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Abbvie immunogen and stay connected to the pulse of your community

Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio

Danish drugmaker Genmab said Wednesday it plans to acquire U.S. biotech firm ProfoundBio for $1.8 billion in cash to expand its cancer treatment portfolio.

Denmark , Danish , Ambrx-biopharma , Abbvie-immunogen , Fusion-pharmaceuticals , Profoundbio-inc , Chief-executive-officer , Depositary-receipts ,

Federal Antitrust Enforcement in Health Care: 2023 Year in Review–Part 3 | Manatt, Phelps & Phillips, LLP

In 2023, the DOJ continued its aggressive criminal antitrust enforcement agenda in health care, with mixed results in labor markets. In speeches, the DOJ asserted that its commitment to...

California , United-states , Maine , Florida , American , Alex-kacik , Dan-papscun , Abbvie-immunogen , Dennis-hoey , Abbvie-cerevel , Phelps-phillips , Diane-bartz

Consumer Sentiment Rises as Inflation Expectations Fall

A 13% uptick in the University of Michigan consumer sentiment index bodes well. Plus, investment newsletter commentary on copper prices, stock-market gains,...

Japan , Michigan , United-states , China , Japanese , Roukaya-ibrahim , Udith-sikand , Timothy-brackett , Joanne-hsu , Michael-shaoul , Abbvie-immunogen , Jared-holz

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio

AbbVie is buying rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment.

Richard-gomez , Abbvie-immunogen ,